ich habe mich zum Glück heute nochmals mit zusätzlichen Stückzahlen eingedeckt.
Anzeige
Meldung des Tages: Doppelter Hebel: 2026 – das Jahr für diesen Med-Tech SmallCap!
Neuester,
zuletzt geles. Beitrag
Antworten | Börsen-Forum Übersicht
Zurück
Weiter
... 80 81 82 84 85 86 ...
Antworten | Börsen-Forum Übersicht
Zurück
Weiter ... 80 81 82 84 85 86 ...
GPC auf dem Weg...
Beiträge:
4.671
Zugriffe: 896.092 / Heute: 44
Zugriffe: 896.092 / Heute: 44
|
Werbung
Entdecke die beliebtesten ETFs von SPDR
bigcharts.marketwatch.com/charts/...;rand=2609&mocktick=1" style="max-width:560px" border="0" />
bigcharts.marketwatch.com/charts/...;rand=2728&mocktick=1" style="max-width:560px" border="0" />
bigcharts.marketwatch.com/charts/...;rand=3934&mocktick=1" style="max-width:560px" border="0" />
Erstaunliches Volumen.
Aber insider sinds garantiert nicht. img.wallstreet-online.de/smilies/rolleyes.gif" style="max-width:560px" />
Adds details, background, byline)
By Debra Sherman
CHICAGO, June 4 (Reuters) - A chemotherapy pill to treat advanced prostate cancer that had failed to respond to conventional treatments was successful in reducing the risk of disease progression, researchers said on Monday.
The Phase III results of a clinical trial involving 950 patients, presented in Chicago at the annual American Society of Clinical Oncology, showed the platinum-based drug known as satraplatin plus Pharmion's (PHRM.O: Quote, Profile , Research) steroid prednisone halted growth of the tumor in a third of cases compared with those given placebo and prednisone.
Reuters Pictures
Editors Choice: Best pictures
from the last 24 hours.
View Slideshow
Satraplatin, currently under U.S. Food and Drug Administration review as a treatment for advanced prostate cancer, is sold by GPC Biotech AG (GPCB.O: Quote, Profile , Research) of Germany. It was licensed from Spectrum Pharmaceuticals Inc. (SPPI.O: Quote, Profile , Research) and Pharmion. The study was funded by GPC and Pharmion.
"If approved, satraplatin will represent an important new therapy option for patients with advanced prostate cancer whose prior chemotherapy has failed," said Dr. Cora Sternberg, chief of the department of oncology at the San Camillo and Forlanini Hospitals in Rome and one of the investigators of the study.
The study also met its secondary goal of reducing pain. Twenty-four percent of those who received the drug reported less pain versus 14 percent in the control group.
The drug works by binding to DNA of cancer cells and makes the cell incapable of dividing, causing them to stop growing. Eventually this leads to the death of the cancer cells.
By Debra Sherman
CHICAGO, June 4 (Reuters) - A chemotherapy pill to treat advanced prostate cancer that had failed to respond to conventional treatments was successful in reducing the risk of disease progression, researchers said on Monday.
The Phase III results of a clinical trial involving 950 patients, presented in Chicago at the annual American Society of Clinical Oncology, showed the platinum-based drug known as satraplatin plus Pharmion's (PHRM.O: Quote, Profile , Research) steroid prednisone halted growth of the tumor in a third of cases compared with those given placebo and prednisone.
Reuters Pictures
Editors Choice: Best pictures
from the last 24 hours.
View Slideshow
Satraplatin, currently under U.S. Food and Drug Administration review as a treatment for advanced prostate cancer, is sold by GPC Biotech AG (GPCB.O: Quote, Profile , Research) of Germany. It was licensed from Spectrum Pharmaceuticals Inc. (SPPI.O: Quote, Profile , Research) and Pharmion. The study was funded by GPC and Pharmion.
"If approved, satraplatin will represent an important new therapy option for patients with advanced prostate cancer whose prior chemotherapy has failed," said Dr. Cora Sternberg, chief of the department of oncology at the San Camillo and Forlanini Hospitals in Rome and one of the investigators of the study.
The study also met its secondary goal of reducing pain. Twenty-four percent of those who received the drug reported less pain versus 14 percent in the control group.
The drug works by binding to DNA of cancer cells and makes the cell incapable of dividing, causing them to stop growing. Eventually this leads to the death of the cancer cells.
um SPPI kreisen, vorrangig.
Weiter vielleicht neue Daten zum Überleben?
In neun Stunden wissen wir wohl mehr. ;o)
Weiter vielleicht neue Daten zum Überleben?
In neun Stunden wissen wir wohl mehr. ;o)
Oder vielleicht Gerüchteküchendüfte? Übernahmephantasie?
Mhmmmmm, vielleicht spinnen die Ami`s auch nur. ;o)
Gute Nacht.
Mhmmmmm, vielleicht spinnen die Ami`s auch nur. ;o)
Gute Nacht.
GPCB: To Present At ASCO 2007 Conference @ 19:00 ET
Company representatives of Gpc Bitoech AG ADS (NasdaqNM: GPCB) will be presenting at the 43rd Annual Meeting of the American Society of Clinical Oncology today. The Company's presentation is scheduled to begin at 19:00 ET.
Misc Releated Info:
** Original Confirmation
** Conference Information:
43rd Annual Meeting of the American Society of Clinical Oncology
Conference Dates: 06/01/2007-06/05/2007
McCormick Place
Chicago, IL
www.asco.org/portal/site/ASCO
GPCB: To Present At ASCO 2007 Conference @ 19:00 ET
Company representatives of Gpc Bitoech AG ADS (NasdaqNM: GPCB) will be presenting at the 43rd Annual Meeting of the American Society of Clinical Oncology today. The Company's presentation is scheduled to begin at 19:00 ET.
Misc Releated Info:
** Original Confirmation
** Conference Information:
43rd Annual Meeting of the American Society of Clinical Oncology
Conference Dates: 06/01/2007-06/05/2007
McCormick Place
Chicago, IL
www.asco.org/portal/site/ASCO
Pharmion And GPC Biotech Say Additional New Data From Satraplatin SPARC Phase 3 Investigational Trial Presented
(RTTNews) - Pharmion Corp. (PHRM) and GPC Biotech AG (GPCB) announced the presentation of additional data from the double-blind, randomized satraplatin Phase 3 registrational trial, the SPARC trial (Satraplatin and Prednisone Against Refractory Cancer).
The SPARC trial is evaluating satraplatin plus prednisone versus placebo plus prednisone in 950 patients with hormone-refractory prostate cancer (HRPC) whose prior chemotherapy has failed. A New Drug Application (NDA) for satraplatin is currently under priority review by the U.S. Food and Drug Administration.
For each of the 20 subsets presented today, the reduction in relative risk of disease progression ranged from 26% to 46%, corresponding to hazard ratios between 0.74 and 0.54.
Preliminary data from Phase 2 trial evaluating satraplatin plus Taxol in non-small cell lung cancer also published in ASCO educational book
Preliminary data from an ongoing Phase 2 trial evaluating satraplatin plus Taxol (paclitaxel) in the first-line treatment of patients with advanced non-small cell lung cancer were also published. Data from 24 patients were available for analysis; a total of approximately 40 patients are expected to be enrolled in the study.
(RTTNews) - Pharmion Corp. (PHRM) and GPC Biotech AG (GPCB) announced the presentation of additional data from the double-blind, randomized satraplatin Phase 3 registrational trial, the SPARC trial (Satraplatin and Prednisone Against Refractory Cancer).
The SPARC trial is evaluating satraplatin plus prednisone versus placebo plus prednisone in 950 patients with hormone-refractory prostate cancer (HRPC) whose prior chemotherapy has failed. A New Drug Application (NDA) for satraplatin is currently under priority review by the U.S. Food and Drug Administration.
For each of the 20 subsets presented today, the reduction in relative risk of disease progression ranged from 26% to 46%, corresponding to hazard ratios between 0.74 and 0.54.
Preliminary data from Phase 2 trial evaluating satraplatin plus Taxol in non-small cell lung cancer also published in ASCO educational book
Preliminary data from an ongoing Phase 2 trial evaluating satraplatin plus Taxol (paclitaxel) in the first-line treatment of patients with advanced non-small cell lung cancer were also published. Data from 24 patients were available for analysis; a total of approximately 40 patients are expected to be enrolled in the study.
bei seiner Order eingegeben und somit GPC zu einem echten Vorzugspreis gekauft.
Sieht charttechnisch ja ganz schön aus, bringt uns aber anscheinend nicht viel.
War wohl nur ein kleiner Vorgeschmackt darauf, was so alles mit GPC passieren kann.
Wenn es hoch geht, dann ruck zuck !
Gruß Byblos
Sieht charttechnisch ja ganz schön aus, bringt uns aber anscheinend nicht viel.
War wohl nur ein kleiner Vorgeschmackt darauf, was so alles mit GPC passieren kann.
Wenn es hoch geht, dann ruck zuck !
Gruß Byblos
After Hours
Time (ET) Price Share Volume
19:16 $ 33.60 100
18:21 $ 33.48 300
17:34 $ 33.18 100
17:34 $ 33.18 400
17:34 $ 33.26 100
17:34 $ 33.28 100
16:29 $ 33.00 200
16:10 $ 32.90 200
16:10 $ 32.97 250
16:10 $ 32.98 550
16:10 $ 32.98 450
16:10 $ 33.00 100
16:10 $ 33.00 800
Sollten heute noch einmal solche tollen Vorzugspreise von den Ami's gezahlt werden,
müßte man ja glatt überlegen seine Stücke unter die Ami's zu werfen und sie dann am folgenden Tag in good old Germany billig wieder kaufen. :-)
Die Sonne scheint, die Vögel picken, es ist Zeit ......
Have a nice day !
Gruß Byblos
Time (ET) Price Share Volume
19:16 $ 33.60 100
18:21 $ 33.48 300
17:34 $ 33.18 100
17:34 $ 33.18 400
17:34 $ 33.26 100
17:34 $ 33.28 100
16:29 $ 33.00 200
16:10 $ 32.90 200
16:10 $ 32.97 250
16:10 $ 32.98 550
16:10 $ 32.98 450
16:10 $ 33.00 100
16:10 $ 33.00 800
Sollten heute noch einmal solche tollen Vorzugspreise von den Ami's gezahlt werden,
müßte man ja glatt überlegen seine Stücke unter die Ami's zu werfen und sie dann am folgenden Tag in good old Germany billig wieder kaufen. :-)
Die Sonne scheint, die Vögel picken, es ist Zeit ......
Have a nice day !
Gruß Byblos
Vielleicht auch ne hochraffinierte Transaktion, die beim Normalbürger schon im Begriffsansatz ein Schleudertrauma auslöst. ;o)
In USA
"Pre-Market: 31.20 1.61 (4.91%) as of 7:14AM ET on 06/05/07"
Wird mal Zeit, dass bei uns einer die Kuh vom Eis nimmt.
"Pre-Market: 31.20 1.61 (4.91%) as of 7:14AM ET on 06/05/07"
Wird mal Zeit, dass bei uns einer die Kuh vom Eis nimmt.
"Pre-Market: 29.11 3.70 (11.28%) as of 8:33AM ET on 06/05/07"
Das nächtliche Manöver könnte ja auch als Finte im engen Markt gedeutet werden!?
"Jemand" wollte in Europa günstig verkaufen und hat deshalb vorher im engen Markt USA den Kurs kurzfristig hochgetrieben und "gehofft", dass TecDAX blind folgt.
Noch jemand anders bessere Verfolgungswahnundverschwörungsausdünstungen?? ;o)
Das nächtliche Manöver könnte ja auch als Finte im engen Markt gedeutet werden!?
"Jemand" wollte in Europa günstig verkaufen und hat deshalb vorher im engen Markt USA den Kurs kurzfristig hochgetrieben und "gehofft", dass TecDAX blind folgt.
Noch jemand anders bessere Verfolgungswahnundverschwörungsausdünstungen?? ;o)
Dendreon Gets Its Funding
By Brian Lawler June 5, 2007
67
Recommendations
Last week, I mused that after getting a nearly 100% rise in share price at one point last Thursday, it would be a good time for Dendreon (Nasdaq: DNDN) to do a dilutive financing and to take advantage of its high share price.
The press release that Dendreon issued last week, and which bumped up shares, offered no substantive news. It was the sort of thing that development-stage biotechs with a high percentage of retail investors like to announce right before going hat in hand to institutional investors to raise money.
The stock spiked on the announcement that showing a survival benefit in its ongoing phase 3 study for lead drug Provenge would probably be enough for FDA regulatory approval (something many investors already knew). And less than two business days after that news, Dendreon said that an up to $100 million convertible debt offering is in the works.
Dendreon needs the cash, and it was only a matter of time as to when it would do the offering. By doing its convertible debt offering now rather than waiting until after the interim results of the IMPACT/D9902b study come out next year, might Dendreon be signaling to investors that it thinks shares are overvalued at today's price? I gave my opinion on this issue when I wrote:
Compared to other biopharmas with oncology compounds in similar stages of development, shares of Dendreon appear at least $150 million overvalued on a relative basis with its $750 million market cap after this run-up in price yesterday.
Shares are down somewhat since then, but still have further to fall until I think they are fairly valued on a relative basis. Furthermore, Dendreon has a completely unproven treatment modality, and Provenge is most likely four years away from the market, if at all. That the biotech can fetch a market cap nearly two-thirds that of GPC Biotech (Nasdaq: GPCB), despite the strong odds that GPC has the next prostate cancer compound to gain marketing approval in the U.S. later this year, shows that something is just not jibing with Dendreon's valuation and reality.
Investors who fail to pay attention to relative valuations of the different stocks in the development-stage biotech space do so at their own peril. Dendreon's CEO and two board members sold a combined amount of stock worth over $4 million immediately after the positive advisory panel vote and before the approvable letter. This, combined with the company issuing debt at today's prices, should give investors a good idea of what Dendreon's leadership thinks its shares are worth.
Looking for more Foolish drug stock coverage? Check out the Fool's market-beating Rule Breakers newsletter. You can check out all our recommendations as well as get access to our message boards and exclusive content with a 30-day free trial.
Fool contributor Brian Lawler does not own shares of any company mentioned in this article. The Fool has a disclosure policy.
By Brian Lawler June 5, 2007
67
Recommendations
Last week, I mused that after getting a nearly 100% rise in share price at one point last Thursday, it would be a good time for Dendreon (Nasdaq: DNDN) to do a dilutive financing and to take advantage of its high share price.
The press release that Dendreon issued last week, and which bumped up shares, offered no substantive news. It was the sort of thing that development-stage biotechs with a high percentage of retail investors like to announce right before going hat in hand to institutional investors to raise money.
The stock spiked on the announcement that showing a survival benefit in its ongoing phase 3 study for lead drug Provenge would probably be enough for FDA regulatory approval (something many investors already knew). And less than two business days after that news, Dendreon said that an up to $100 million convertible debt offering is in the works.
Dendreon needs the cash, and it was only a matter of time as to when it would do the offering. By doing its convertible debt offering now rather than waiting until after the interim results of the IMPACT/D9902b study come out next year, might Dendreon be signaling to investors that it thinks shares are overvalued at today's price? I gave my opinion on this issue when I wrote:
Compared to other biopharmas with oncology compounds in similar stages of development, shares of Dendreon appear at least $150 million overvalued on a relative basis with its $750 million market cap after this run-up in price yesterday.
Shares are down somewhat since then, but still have further to fall until I think they are fairly valued on a relative basis. Furthermore, Dendreon has a completely unproven treatment modality, and Provenge is most likely four years away from the market, if at all. That the biotech can fetch a market cap nearly two-thirds that of GPC Biotech (Nasdaq: GPCB), despite the strong odds that GPC has the next prostate cancer compound to gain marketing approval in the U.S. later this year, shows that something is just not jibing with Dendreon's valuation and reality.
Investors who fail to pay attention to relative valuations of the different stocks in the development-stage biotech space do so at their own peril. Dendreon's CEO and two board members sold a combined amount of stock worth over $4 million immediately after the positive advisory panel vote and before the approvable letter. This, combined with the company issuing debt at today's prices, should give investors a good idea of what Dendreon's leadership thinks its shares are worth.
Looking for more Foolish drug stock coverage? Check out the Fool's market-beating Rule Breakers newsletter. You can check out all our recommendations as well as get access to our message boards and exclusive content with a 30-day free trial.
Fool contributor Brian Lawler does not own shares of any company mentioned in this article. The Fool has a disclosure policy.
Versucht nicht den Markt zu interpretieren. Wenn im August alles glatt läuft, geht die Aktie innerhalb weniger Tage auf 30 bis 35€, genauso wie sie früher lange zwischen 9 und 12 schwankte und dann auf über 20 € in kürzester Zeit hochschnellte. Läuft es im August schief, so geht die Aktie auf 14 bis 16 € zurück. Was ist wahrscheinlicher? Die Zulassung in USA und damit Kurse über 30 €, aber wir sprechen von Börse und ein Restrisiko bleibt immer. Also Geduld bis August.
habe ich doch meine Anteile zu 37 Dollar vor zwei Tagen in den USA verkauft.
Ich warte lieber noch zwei Monate, dann krieg ich fürs Papierchen 35 bis 45 €.
Ich warte lieber noch zwei Jahre. Dann krieg ich fürs Papierchen 80 - 100 €.
;o)
Ich warte lieber noch zwei Jahre. Dann krieg ich fürs Papierchen 80 - 100 €.
;o)
Für 37 US Dollar verkauft ! Super ! Wen interessiert es hier.
Das empfinde ich als wichtigtuerei und wertet einen in der Glaubwürdigkeit ganz schön ab.
Gruenelinie muß ich dafür ein Lob aussprechen, denn er bleibt immer auf der Matte und hängt sich nicht so weit aus dem Fenster !
Leute, behaltet die Ruhe !
Auf Sicht von 1,5 Jahren soll GPC ein Kursziel von ca. 78 €uro haben. ( wurde mir von Institioneller Seite aus erzählt. Ob die Recht haben oder nicht, entscheidet gleich das Licht ( Mitte August + followig Time ))
Ich lasse meine Stücke liegen, egal, was der Kurs bis August so alles macht.
Gruß Byblos
Das empfinde ich als wichtigtuerei und wertet einen in der Glaubwürdigkeit ganz schön ab.
Gruenelinie muß ich dafür ein Lob aussprechen, denn er bleibt immer auf der Matte und hängt sich nicht so weit aus dem Fenster !
Leute, behaltet die Ruhe !
Auf Sicht von 1,5 Jahren soll GPC ein Kursziel von ca. 78 €uro haben. ( wurde mir von Institioneller Seite aus erzählt. Ob die Recht haben oder nicht, entscheidet gleich das Licht ( Mitte August + followig Time ))
Ich lasse meine Stücke liegen, egal, was der Kurs bis August so alles macht.
Gruß Byblos
stellt sich die frage jetzt zu verkaufen und wieder günstiger einzusteigen oder jetzt nachzukaufen :(
Erholung kommen. seufz
Wie soll den heute noch mit einer Erholung gerechnet werden, wenn die EZB die Leitzinsen gerade esrt um 25 Punkte angehoben hat und mit einer weiteren Erhöhung im September gerechnet wird.
Kommische Logik - Ab 19E steig ich erst bei GPC ein - Stopp bei 16.
@ Brotkorb - Verkaufe lieber Deine Positionen und steige 2€ darunter wieder ein, in den nächsten zwei Wochen wird es keine News zu GPC geben.
Kommische Logik - Ab 19E steig ich erst bei GPC ein - Stopp bei 16.
@ Brotkorb - Verkaufe lieber Deine Positionen und steige 2€ darunter wieder ein, in den nächsten zwei Wochen wird es keine News zu GPC geben.
Es gibt keine neuen Beiträge.
|
Neueste Beiträge aus dem GPC Biotech Forum
| Wertung | Antworten | Thema | Verfasser | letzter Verfasser | letzter Beitrag | |
| 14 | DANKE USB Warburg !!! Danke,danke,danke..... | Drogo | Rosebud | 25.04.21 02:51 | ||
| 28 | ABIT: +13% auf 55 Euro. Ich Depp habe zu 50 vorhin verkauft... Unverbesserlich! :( o.T. | Dauberus | Dauberus | 25.04.21 00:02 | ||
11 | 103 | Neues aus der Welt der Antikörper und Immunother. | KliP | Heron | 10.09.13 10:53 | |
| 5 | 43 | Biotechnologie? Hör mir bloss auf ! | Parocorp | andyy | 08.12.10 09:27 | |
| 48 | 4.670 | GPC auf dem Weg... | kater123 | techval | 07.10.09 19:30 |